major breakthrough is on the horizon for Crohn's disease

    A major breakthrough is on the horizon for Crohn's disease. The drug will be called infliximab (Avakine) Centocor.

    Crohn's is an autoimmune disease. Tumor necrosis factor (TNF) is involved. Avakine is a monoclonal antibody that blocks this factor...and slows the inflammation.

    In fact, it shows dramatic improvement in two-thirds of patients with moderate to severe Crohn's. One injection gives benefits lasting several months.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 300+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote